Previously, another DP1 antagonist, laropiprant (MK-0524), was shown to prevent nasal congestion induced by PGD2 in healthy subjects (101) but failed in phase II trials in allergic rhinitis and asthma (102). This evidence concerns the gene HPGDS and asthma.